Stocks Health care BCAX
NASDAQ · Health careBicara Therapeutics Inc. (BCAX)
It posted a net loss of $185.4M. In fiscal 2025 capital spending exceeded operating cash flow by $107.1M. At June 30, 2026 it held $96.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Bicara Therapeutics Inc. does
Bicara Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BCAX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$138M | -$2.52 | -$107.1M |
| 2024 | n/a | -$68M | -$4.05 | -$74.8M |
| 2024 | n/a | -$52M | -$89.61 | -$46.2M |
Latest SEC filings
What Bicara Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 25, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- July 28, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- June 10, 2026
- May 21, 2026Other event 8-K
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Bicara Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $400.7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 8, 2026 | Cohlhepp RyanPresident, COO & Interim CEO, Director | Exercised options | 17,500 | $66.3K |
| September 8, 2026 | Cohlhepp RyanPresident, COO & Interim CEO, Director | Soldpre-planned (10b5-1) | 14,058 | $320.1K |
| September 8, 2026 | Cohlhepp RyanPresident, COO & Interim CEO, Director | Soldpre-planned (10b5-1) | 3,442 | $80.7K |
Questions about BCAX
What does Bicara Therapeutics Inc. do?
Bicara Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BCAX.
Is Bicara Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $185.4M.
When did Bicara Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 10, 2026.
Similar companies
Compare BCAX with
Follow BCAX
Get an email when Bicara Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BCAX: get an email when it filesWhere the numbers come from
Financial figures are the values Bicara Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.